The Chiesi Total Care Program Assists With:

Dedicated Total
Care Team

Once you are enrolled into the Chiesi Total Care program, your Patient Service Coordinator (PSC) is your go-to person for all things Chiesi Total Care. Have a question or concern? Talk to your PSC

Injection
support

  • Ensures medication is delivered right to where you need it
  • Answers questions about administration, storage and disposal, and more
  • You will also have access to a pharmacist, Reimbursement Support Specialists, nursing support, and more

Commercial
insurance

If you have private insurance through your job or your own business

Government
insurance

If you have Medicare, Medicaid, Veterans Affairs Healthcare, or other similar government insurance

No insurance

If you have no insurance, you may be eligible for financial assistance

Chiesi Total Care Patient Assistance Program

For patients who meet the financial requirements of the Chiesi Total Care Patient Assistance Program, you may be eligible to receive your medication at no cost.

Program Eligibility:

  • You are enrolled in Chiesi Total Care. (Enrollment form can be found here)
  • You have a valid prescription for a US Food and Drug Administration (FDA)-approved indication for Revcovi®
  • You do not receive health care benefits from a federal or state-funded plan or program
  • You are uninsured or underinsured (lack of coverage for their medication)
  • If you have commercial insurance, you may be eligible for the Chiesi Total Care Copay Assistance Program
  • You must have an annual household income that does not exceed 500% of the current Federal Poverty Level (FPL)*
  • You must be a resident of the United States or one of its territories

*Please refer to the full Terms and Conditions for additional eligibility requirements.

Josh, actual Revcovi
Patient and partner
For more information about Revcovi, visit revcovi.com.
Revcovi® (elapegademase-lvlr)
DOWNLOAD FULL PRESCRIBING INFORMATION FOR REVCOVI

Ashley, actual
Revcovi patient
For more information about Revcovi, visit revcovi.com

INDICATION

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • If you have lower than normal platelet counts, you may be at increased risk of bleeding at the injection site. Your doctor should not prescribe Revcovi if you have severely low blood platelet counts.
  • There may be a delay in improvement of your immune system’s function after starting Revcovi treatment. During this delay, it is important to be protected from exposure to infections until your immune system improves.

What are the possible side effects of Revcovi?

  • Cough and vomiting were the most common side effects reported by patients receiving Revcovi.
  • Based on reports of side effects of other enzyme replacement therapies used to treat ADA-SCID, which are similar to Revcovi, patients taking Revcovi may also experience:
    • Blood and blood cell–related problems: red blood cells being destroyed faster than they can be made, resulting in anemia; and higher or lower than normal number of platelets in the blood
    • Skin-related problems: redness and itching at the injection site
    • Cancers of the immune system called lymphomas

What types of monitoring will be needed while I am taking Revcovi?

  • Continuous therapy and adherence to the recommended drug schedule is important for the success of the treatment.
  • While you are being treated with Revcovi, your doctor will need to do blood tests to monitor the levels of ADA activity and metabolites and overall immune function.
  • This monitoring will ensure you are maintaining appropriate levels for therapeutic benefit. If an ongoing decline in your blood’s measured adenosine deaminase (ADA) activity occurs, your immune function and clinical status will be monitored closely and precautions will be taken to help reduce your risk of infection.

What is known about taking Revcovi during pregnancy?

  • If you are pregnant or planning to become pregnant, or breastfeeding or planning to breastfeed, please talk to your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information.

INDICATION

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • If you have lower than normal platelet counts, you may be at increased risk of bleeding at the injection site. Your doctor should not prescribe Revcovi if you have severely low blood platelet counts.
  • There may be a delay in improvement of your immune system’s function after starting Revcovi treatment. During this delay, it is important to be protected from exposure to infections until your immune system improves.

What are the possible side effects of Revcovi?

  • Cough and vomiting were the most common side effects reported by patients receiving Revcovi.
  • Based on reports of side effects of other enzyme replacement therapies used to treat ADA-SCID, which are similar to Revcovi, patients taking Revcovi may also experience:
    • Blood and blood cell–related problems: red blood cells being destroyed faster than they can be made, resulting in anemia; and higher or lower than normal number of platelets in the blood
    • Skin-related problems: redness and itching at the injection site
    • Cancers of the immune system called lymphomas

What types of monitoring will be needed while I am taking Revcovi?

  • Continuous therapy and adherence to the recommended drug schedule is important for the success of the treatment.
  • While you are being treated with Revcovi, your doctor will need to do blood tests to monitor the levels of ADA activity and metabolites and overall immune function.
  • This monitoring will ensure you are maintaining appropriate levels for therapeutic benefit. If an ongoing decline in your blood’s measured adenosine deaminase (ADA) activity occurs, your immune function and clinical status will be monitored closely and precautions will be taken to help reduce your risk of infection.

What is known about taking Revcovi during pregnancy?

  • If you are pregnant or planning to become pregnant, or breastfeeding or planning to breastfeed, please talk to your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Full Prescribing Information.